quantifying the anemia benefit of momelotinib in mf: analysis of data from simplify-1 & simplify-2
Published 4 months ago • 62 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
2:26
assessing the impact of momelotinib on transfusion burden in mf: analysis of simplify-1 & momentum
-
1:45
momelotinib vs soc in patients with mf and anemia: an analysis from the simplify-2 trial
-
1:58
transfusion-independence associated with os in simplify-1 and simplfy-2
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
3:00
the promise of momelotinib in the treatment of myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
4:48
an insight into the management of cytopenias in mf
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
47:31
hematology - hematologic disorders (2019 board review series)
-
8:58
hy usmle q #868 – hematology
-
5:56
hematologic system examination
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
1:30
addressing unmet needs in myelofibrosis: alleviating anemia
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:08
real-world analysis of the most study: factors impacting progression to mf in patients with et
-
1:52
maic of momelotinib versus fedratinib safety in myelofibrosis
-
0:55
a pooled analysis to determine the optimal ki-67 index cut-off point for predicting outcomes in mcl
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
3:44
phase ii study update of navtemadlin in patients with myelofibrosis r/r to ruxolitinib